Synthetic Biologics, Inc. (NYSEAMERICAN:SYN – Get Free Report)’s stock price traded up 1% during trading on Monday . The stock traded as high as $1.02 and last traded at $1.02. 57,700 shares were traded during trading, a decline of 71% from the average session volume of 197,338 shares. The stock had previously closed at $1.01.
Synthetic Biologics Stock Performance
The firm has a market cap of $16.16 million, a price-to-earnings ratio of -0.84 and a beta of 1.38.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc, a clinical-stage company, develops therapeutics to treat diseases in areas of high unmet need. The company's lead product candidates include SYN-004 designed to degrade various commonly used intravenous beta-lactam antibiotics in gastrointestinal (GI) tract for the prevention of microbiome damage, clostridium difficile infection (CDI), overgrowth of pathogenic organisms, the emergence of antimicrobial resistance (AMR), and acute graft-versus-host-disease (aGVHD) in allogeneic hematopoietic cell transplant recipients; and SYN-020, a recombinant oral formulation for the enzyme intestinal alkaline phosphatase to treat both local GI and systemic diseases.
Featured Articles
- Five stocks we like better than Synthetic Biologics
- The Basics of Support and Resistance
- Should You Invest in Treasury Bills?
- How to Invest in Tech StocksĀ and Top Tech Stocks to Consider
- Analysts Think There’s Still Time to Get in on Edgewise, Up 332%
- How to Calculate Inflation Rate
- 3 Stocks Raising Dividends 4X Higher Than Inflation
Receive News & Ratings for Synthetic Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics and related companies with MarketBeat.com's FREE daily email newsletter.